Sinarest and Treprostinil Sodium

• Generic Name: acetaminophen / chlorpheniramine / pseudoephedrine
• Dosage Forms: n.a.
• Other Brand Names: Complete Sinus Relief, Sinadrin PE Complete Sinus Relief, Alka-Seltzer Plus Cold Liquigel, Allerest Headache Strength, Allerest Sinus, Cold Medicine Plus, Comtrex Allergy Sinus, Comtrex Allergy Sinus Maximum Strength, Comtrex Allergy Sinus Night and Day, Kolephrin, Sinarest, Sinutab Ex-Strength, Theraflu Cold & Sore Throat, Theraflu Flu & Sore Throat, Theraflu Maximum Strength, Singlet, Simplet, Tricom, Theraflu Flu and Cold Medicine Powder, Codimal, Tylenol Gelcap Allergy Sinus, Theraflu Sore Throat Maximum Strength, Tylenol Cold-Child, Tylenol Allergy Sinus Caplet, Tylenol Allergy Sinus Geltab, Sinarest Extra Strength, Children's Tylenol Cold Multi-Symptom, Tylenol Allergy Sinus Gelcap, Children's Tylenol Cold, Triaminicin, Sinutab Maximum Strength Caplets, Sinutab Maximum Strength Non-Drowsy, Actifed Cold & Sinus, Allergy Sinus Maximum Strength, EQ Cold Plus

Acetaminophen is a pain reliever and fever reducer.

Chlorpheniramine is an antihistamine that reduces the effects of natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.

Pseudoephedrine is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).

Sinarest (Acetaminophen, chlorpheniramine, and pseudoephedrine) is a combination medicine used to treat headache, fever, body aches, runny or stuffy nose, sneezing, itching, watery eyes, and sinus congestion caused by allergies, the common cold, or the flu.

Sinarest may also be used for purposes not listed in this medication guide.

• Generic Name: treprostinil
• Dosage Forms: n.a.
• Other Brand Names: Orenitram, Remodulin, Tyvaso, Tyvaso Refill Kit, Tyvaso Starter Kit

Treprostinil is used parenterally (as a continuous sub-Q or IV infusion) for treatment of pulmonary arterial hypertension (PAH; WHO group 1) to reduce symptoms associated with exercise; efficacy established in patients with NYHA functional class II–IV (predominantly class III) PAH (idiopathic, heritable, or associated with connective tissue disease or congenital systemic-to-pulmonary shunts). Also used parenterally to reduce rate of clinical deterioration in patients who require conversion from epoprostenol therapy; carefully consider risks and benefits of each drug prior to transition.

Treprostinil is used by oral inhalation to improve exercise ability in patients with PAH; efficacy established principally in patients with NYHA functional class III PAH (idiopathic, heritable, or associated with connective tissue disease). Controlled clinical experience with orally inhaled treprostinil is based primarily on short-term trials in patients receiving the drug as add-on therapy to bosentan or sildenafil.

Treprostinil diolamine is used orally (as extended-release tablets) to improve exercise capacity in patients with PAH; efficacy established principally in patients with WHO functional class II–III PAH (idiopathic, heritable, or associated with connective tissue disease). Oral treprostinil may be more convenient than inhaled or parenteral formulations; however, studies have shown only modest benefits of oral treprostinil on exercise capacity. When the drug is used as the sole vasodilator in patients with PAH, the effect on exercise capacity is approximately 10% of the deficit, and the effect, if any, in combination with other vasodilators is probably even less.

Parenteral or inhaled treprostinil is recommended as one of several treatment options for initial management of PAH in patients with NYHA/WHO functional class III or IV symptoms who are not candidates for calcium-channel blocker therapy or in whom such therapy failed. While oral treprostinil may be a potential initial treatment option for patients with less severe PAH, additional studies are needed.

Individualize choice of therapy; consider factors such as disease severity, route of administration, potential adverse effects and costs of treatment, clinician experience, and patient preference.

Combination therapy with drugs that target different pathophysiologic pathways of the disease should be considered since such therapy may provide additive and/or synergistic benefits. Results of studies evaluating combination therapy with treprostinil have been variable; some studies (inhaled treprostinil in combination with an endothelin-receptor antagonist or a PDE type 5 inhibitor) demonstrated improvements in 6-minute walking distance, while other studies (oral treprostinil with an endothelin-receptor antagonist and/or a PDE type 5 inhibitor) have not shown benefit.

Treprostinil and treprostinil diolamine have been designated orphan drugs by FDA for treatment of PAH.